Back to top

crispr: Archive

Sundeep Ganoria

CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?

Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.

VRTXPositive Net Change BEAMPositive Net Change EDITPositive Net Change CRSPNegative Net Change